Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 8/2020

01-08-2020 | Original Article

The effect of mirabegron on bladder blood flow in a rat model of bladder outlet obstruction

Authors: Tsuyoshi Majima, Yoshihisa Matsukawa, Yasuhito Funahashi, Masashi Kato, Tokunori Yamamoto, Momokazu Gotoh

Published in: World Journal of Urology | Issue 8/2020

Login to get access

Abstract

Purpose

To evaluate the effects of mirabegron on bladder blood flow in a rat model of bladder outlet obstruction (BOO).

Methods

Adult female Sprague–Dawley rats were divided into three groups based on whether they underwent a sham operation (sham group) or an operation to establish partial BOO (BOO and BOO + mirabegron groups). The BOO + mirabegron group was treated with mirabegron (0.3 mg/kg/h, subcutaneously) for 14 days. Subsequently, we performed continuous cystometry, bladder blood flow measurements with a 2D laser blood flow imager, hematoxylin–eosin staining of the bladder tissue, and malondialdehyde (MDA) measurements in the bladder tissue.

Results

Cystometry revealed significantly higher peak pressure, more residual urine volume, and lower voiding efficiency in the BOO and BOO + mirabegron groups than in the sham group. The BOO + mirabegron group had significantly fewer non-voiding contractions (NVCs) than the BOO group, while the latter had more frequent NVCs than the sham group. The BOO and BOO + mirabegron groups had significantly decreased bladder blood flow than the sham group, whereas the BOO + mirabegron group showed significantly increased bladder blood flow than the BOO group. The bladder tissue in the BOO group contained more hypertrophic detrusor muscle compared to the sham group, while mirabegron treatment suppressed detrusor hypertrophy. The MDA levels were significantly higher in the BOO group than in the BOO + mirabegron and sham groups.

Conclusion

Mirabegron treatment significantly improved BOO-induced bladder dysfunction through the amelioration of bladder blood flow.
Literature
1.
Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61:37CrossRef
2.
Milsom I, Abrams P, Cardozo L et al (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87:760CrossRef
3.
Irwin DE, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306CrossRef
4.
Ge TJ, Vetter J, Lai HH (2017) Sleep disturbance and fatigue are associated with more severe urinary incontinence and overactive bladder symptoms. Urology 109:67CrossRef
5.
Jayadevappa R, Chhatre S, Newman DK et al (2018) Association between overactive bladder treatment and falls among older adults. Neurourol Urodyn 37(8):2688–2694CrossRef
6.
Andersson KE, Nomiya M, Yamaguchi O (2015) Chronic pelvic ischemia: contribution to the pathogenesis of lower urinary tract symptoms (LUTS): a new target for pharmacological treatment? Low Urin Tract Symptoms 7:1CrossRef
7.
Majima T, Yamamoto T, Funahashi Y et al (2017) Effect of naftopidil on bladder microcirculation in a rat model of bladder outlet obstruction. Low Urin Tract Symptoms 9:111CrossRef
8.
Inoue S, Saito M, Tsounapi P et al (2012) Effect of silodosin on detrusor overactivity in the male spontaneously hypertensive rat. BJU Int 110:E118CrossRef
9.
Gotoh D, Torimoto K, Tatsumi Y et al (2018) Tadalafil, a phosphodiesterase type 5 inhibitor, improves bladder blood supply and restores the initial phase of lower urinary tract dysfunction in diabetic rats. Neurourol Urodyn 37:666CrossRef
10.
Yamaguchi O, Chapple CR (2007) Beta3-adrenoceptors in urinary bladder. Neurourol Urodyn 26:752CrossRef
11.
Yamaguchi O, Marui E, Kakizaki H et al (2014) Phase III, randomised, double-blind, placebo-controlled study of the 3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int 113:951CrossRef
12.
Kelleher C, Hakimi Z, Zur R et al (2018) Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol 74:324CrossRef
13.
Okutsu H, Matsumoto S, Hanai T, Noguchi Y, Fujiyasu N, Ohtake A, Suzuki M, Sato S, Sasamata M, Uemura H, Takashi K (2010) Effects of tamsulosin on bladder blood flow and bladder function in rats with bladder outlet obstruction. Urology 75:235CrossRef
14.
Kawai Y, Oka M, Kyotani J et al (2012) Effect of the phytotherapeutic agent Eviprostat on the bladder in a rat model of bladder overdistension/emptying. Neurourol Urodyn 32:1031–1037CrossRef
15.
Shafei MN, Niazmand S, Enayatfard L et al (2013) Pharmacological study of cholinergic system on cardiovascular regulation in the cuneiform nucleus of rat. Neurosci Lett 549:12CrossRef
16.
Mannikarottu AS, Disanto ME, Zderic SA et al (2006) Altered expression of thin filament-associated proteins in hypertrophied urinary bladder smooth muscle. Neurourol Urodyn 25:78CrossRef
17.
Greenland JE, Brading AF (2001) The effect of bladder outflow obstruction on detrusor blood flow changes during the voiding cycle in conscious pigs. J Urol 165:245CrossRef
18.
Levin RM, Levin SS, Zhao Y et al (1997) Cellular and molecular aspects of bladder hypertrophy. Eur Urol 32(Suppl 1):15PubMed
19.
Valko M, Leibfritz D, Moncol J et al (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39:44CrossRef
20.
Masuda H et al (2007) Reactive oxygen species mediate detrusor overactivity via sensitization of afferent pathway in the bladder of anaesthetized rats. BJU Int 101:775CrossRef
21.
Frazier EP, Peters SLM, Braverman AS et al (2008) Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and β-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 377:449–462CrossRef
22.
Greenland JE et al (2000) The effect of bladder outlet obstruction on tissue oxygen tension and blood flow in the pig bladder. BJU Int 85(9):1109–1114CrossRef
23.
Belge C, Hammond J, Dubois-Deruy E et al (2014) Enhanced expression of beta3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase. Circulation 129:451CrossRef
24.
Hatanaka T, Ukai M, Watanabe M et al (2013) Effect of mirabegron, a novel beta3-adrenoceptor agonist, on bladder function during storage phase in rats. Naunyn Schmiedebergs Arch Pharmacol 386:71CrossRef
25.
Kitta T, Kanno Y, Chiba H et al (2018) Benefits and limitations of animal models in partial bladder outlet obstruction for translational research. Int J Urol 25:36CrossRef
26.
Pontari MA, Ruggieri MR (1999) Sex differences and role of nitric oxide in blood flow of canine urinary bladder. Am J Physiol 276:R407PubMed
Metadata
Title
The effect of mirabegron on bladder blood flow in a rat model of bladder outlet obstruction
Authors
Tsuyoshi Majima
Yoshihisa Matsukawa
Yasuhito Funahashi
Masashi Kato
Tokunori Yamamoto
Momokazu Gotoh
Publication date
01-08-2020
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 8/2020
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-019-02939-9

Other articles of this Issue 8/2020

World Journal of Urology 8/2020 Go to the issue

Original Article

Treatment of non-obstructive, non-struvite urolithiasis is effective in treatment of recurrent urinary tract infections

Topic Paper

Cost, training and simulation models for robotic-assisted surgery in pediatric urology

Topic Paper

Robot-assisted laparoscopic ureteral reimplantation in children: a valuable alternative to open surgery

Topic Paper

Rare and special robotic surgery indications in the pediatric population: ectopic organs and differences of sexual development

Letter to the Editor

Role of phosphodiesterase inhibitors in stent-related symptoms: a systematic review and meta-analysis

Original Article

Development and validation of a prognostic nomogram for patients with intravesical recurrence after radical nephroureterectomy for non-metastatic upper tract urothelial carcinoma